Literature DB >> 24035828

Matrix metalloproteinase-2 deletions protect against hemorrhagic transformation after 1 h of cerebral ischemia and 23 h of reperfusion.

A Lu1, Y Suofu, F Guan, J P Broderick, K R Wagner, J F Clark.   

Abstract

Although elevated matrix metalloproteinase (MMP)-2 levels were highly related to the degradation of tight junction (TJ) proteins and basal lamina and neuronal injury after ischemia, until very recently, little experimental evidence was available to test the role of the MMP-2 knockout (KO) in blood-brain-barrier (BBB) injury and the development of hemorrhage transformation (HT). Here, we assessed the role of the MMP-2 KO in BBB injury, HT and other brain injuries after 1h of ischemia and 23 h of reperfusion. Middle cerebral artery occlusion (MCAO) was performed in MMP-2 KO mice. Reperfusion was started 1h after the onset of MCAO. All mice were sacrificed 24h after the MCAO. MMP-2 deficiency reduced the decrease in protein levels of collagen IV and cellular membrane occludin (p<0.01 and 0.05 vs. wild-type (WT), respectively) and attenuated increase in cytosol occludin level in ischemic brain (p<0.01 vs. WT). The hemorrhage volume and brain infarction were significantly decreased in both the cortex and striatum in the MMP-2 KO mice (p<0.01 vs. WT). The MMP-2 KO also had reduced brain swelling in the cortex and improved neurological deficits (p<0.01 vs. WT). These studies provide direct evidence that targeting MMP-2 will effectively protect against collagen and occludin loss and HT after ischemia and reperfusion. Published by Elsevier Ltd.

Entities:  

Keywords:  2,3,5-triphenyltetrazolium chloride; BBB; EDTA; FGF; FGF receptor type 1; FGFR1; HT; KO; MCAO; MCID; MMP; MMP-2 knockout; SDS; TJ; TTC; WT; blood–brain barrier; cerebral ischemia; ethylenediaminetetraacetic acid; fibroblast growth factor; hemorrhagic transformation; knockout; matrix metalloproteinase; mice; microcomputer image device; middle cerebral artery occlusion; rCBF; regional cerebral blood flow; sodium dodecyl sulfate; tight junction; wild-type

Mesh:

Substances:

Year:  2013        PMID: 24035828      PMCID: PMC3827875          DOI: 10.1016/j.neuroscience.2013.08.068

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  28 in total

1.  Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice.

Authors:  T Itoh; T Ikeda; H Gomi; S Nakao; T Suzuki; S Itohara
Journal:  J Biol Chem       Date:  1997-09-05       Impact factor: 5.157

2.  Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1.

Authors:  E Levi; R Fridman; H Q Miao; Y S Ma; A Yayon; I Vlodavsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  H(2)O(2)-mediated permeability: role of MAPK and occludin.

Authors:  C G Kevil; T Oshima; B Alexander; L L Coe; J S Alexander
Journal:  Am J Physiol Cell Physiol       Date:  2000-07       Impact factor: 4.249

4.  Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia.

Authors:  M Asahi; T Sumii; M E Fini; S Itohara; E H Lo
Journal:  Neuroreport       Date:  2001-09-17       Impact factor: 1.837

5.  Specific induction of protein kinase C delta subspecies after transient middle cerebral artery occlusion in the rat brain: inhibition by MK-801.

Authors:  S Miettinen; R Roivainen; R Keinänen; T Hökfelt; J Koistinaho
Journal:  J Neurosci       Date:  1996-10-01       Impact factor: 6.167

6.  HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration.

Authors:  Kunyan Zhang; G Angus McQuibban; Claudia Silva; Georgina S Butler; James B Johnston; Janet Holden; Ian Clark-Lewis; Christopher M Overall; Christopher Power
Journal:  Nat Neurosci       Date:  2003-09-21       Impact factor: 24.884

7.  Temporal profile of matrix metalloproteinases and their inhibitors in a human endothelial cell culture model of cerebral ischemia.

Authors:  Björn Reuter; Claus Rodemer; Saskia Grudzenski; Pierre-Olivier Couraud; Babette Weksler; Ignacio A Romero; Stephen Meairs; Peter Bugert; Michael G Hennerici; Marc Fatar
Journal:  Cerebrovasc Dis       Date:  2013-06-25       Impact factor: 2.762

8.  Experimental intracerebral hemorrhage in the mouse: histological, behavioral, and hemodynamic characterization of a double-injection model.

Authors:  Ludmila Belayev; Isabel Saul; Karell Curbelo; Raul Busto; Andrey Belayev; Yongbo Zhang; Panomkhawn Riyamongkol; Weizhao Zhao; Myron D Ginsberg
Journal:  Stroke       Date:  2003-08-14       Impact factor: 7.914

9.  MCP-1 induces activation of MAP-kinases ERK, JNK and p38 MAPK in human endothelial cells.

Authors:  Martina Werle; Ulrike Schmal; Katharina Hanna; Jörg Kreuzer
Journal:  Cardiovasc Res       Date:  2002-11       Impact factor: 10.787

10.  Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia.

Authors:  Aigang Lu; Ruiqiong Ran; Sophie Parmentier-Batteur; Alex Nee; Frank R Sharp
Journal:  J Neurochem       Date:  2002-04       Impact factor: 5.372

View more
  13 in total

Review 1.  Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers.

Authors:  Wei Wang; Mingchang Li; Qianxue Chen; Jian Wang
Journal:  Mol Neurobiol       Date:  2014-11-04       Impact factor: 5.590

Review 2.  Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke.

Authors:  Changjun Yang; Kimberly E Hawkins; Sylvain Doré; Eduardo Candelario-Jalil
Journal:  Am J Physiol Cell Physiol       Date:  2018-10-31       Impact factor: 4.249

3.  Lipid rafts regulate PCB153-induced disruption of occludin and brain endothelial barrier function through protein phosphatase 2A and matrix metalloproteinase-2.

Authors:  Sung Yong Eum; Dima Jaraki; Ibolya E András; Michal Toborek
Journal:  Toxicol Appl Pharmacol       Date:  2015-06-14       Impact factor: 4.219

4.  Disruption of epithelial barrier by quorum-sensing N-3-(oxododecanoyl)-homoserine lactone is mediated by matrix metalloproteinases.

Authors:  Sung Yong Eum; Dima Jaraki; Luc Bertrand; Ibolya E András; Michal Toborek
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

5.  GSK-3β inhibitor TWS119 attenuates rtPA-induced hemorrhagic transformation and activates the Wnt/β-catenin signaling pathway after acute ischemic stroke in rats.

Authors:  Wei Wang; Mingchang Li; Yuefei Wang; Qian Li; Gang Deng; Jieru Wan; Qingwu Yang; Qianxue Chen; Jian Wang
Journal:  Mol Neurobiol       Date:  2015-12-15       Impact factor: 5.590

6.  Recurrent Hemorrhagic Conversion of Ischemic Stroke in a Patient with Mechanical Heart Valve: A Case Report and Literature Review.

Authors:  Micheal Jace Tarver; Tyler Schmidt; Michael T Koltz
Journal:  Brain Sci       Date:  2018-01-07

7.  Icaritin Improves Memory and Learning Ability by Decreasing BACE-1 Expression and the Bax/Bcl-2 Ratio in Senescence-Accelerated Mouse Prone 8 (SAMP8) Mice.

Authors:  Yuan-Yuan Li; Nan-Qu Huang; Fei Feng; Ying Li; Xiu-Mei Luo; Lin Tu; Jing-Qiu Qu; Yi-Man Xie; Yong Luo
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-29       Impact factor: 2.629

8.  Early Gelatinase Activity Is Not a Determinant of Long-Term Recovery after Traumatic Brain Injury in the Immature Mouse.

Authors:  Bridgette D Semple; Linda J Noble-Haeusslein; Major Gooyit; Kayleen G Tercovich; Zhihong Peng; Trung T Nguyen; Valerie A Schroeder; Mark A Suckow; Mayland Chang; Jacob Raber; Alpa Trivedi
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

Review 9.  Hypothermia and brain inflammation after cardiac arrest.

Authors:  Pouya Tahsili-Fahadan; Salia Farrokh; Romergryko G Geocadin
Journal:  Brain Circ       Date:  2018-04-18

10.  Matrix metalloproteinase-2 gene polymorphisms are associated with ischemic stroke in a Hainan population.

Authors:  Fanglin Niu; Boping Wei; Mengdan Yan; Jing Li; Yongri Ouyang; Tianbo Jin
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.